Investing.com - U.S. stock index futures were mixed on Thursday, as investors assessed earnings from chipmaker Micron and geared up for more key economic data this week.

By 05:25 ET, Dow futures had fallen 141 points, or 0.3%, while S&P 500 futures had edged up 17 points, or 0.2%. Nasdaq 100 futures had risen 192 points, or 0.6%.

Alphabet shares rose about 2% in premarket trading after Google unveiled a new artificial intelligence model, Gemini 4 Argon, which the company said delivers stronger coding and cybersecurity performance than rival models at lower prices.

Google said the model will initially be made available to a group of trusted cybersecurity researchers before a broader rollout. Paid API customers and Google AI Ultra subscribers will receive access first, followed by developers, businesses and consumers.

Rocket Lab surged 5.2% in premarket trading to $73.27 after unveiling the largest single commercial launch agreement in its history.

The company signed a 20-mission Electron contract with Tokyo-based Earth observation firm Synspective, covering the launch of 20 StriX synthetic aperture radar satellites from Rocket Lab’s New Zealand facility between 2028 and 2031. The agreement takes Synspective’s total contracted Electron missions to 47 and pushes Rocket Lab’s overall launch backlog above 100 missions for the first time.

Vicor jumped 10.8% in premarket trading to $320.08 after the power component maker raised its third-quarter 2026 sequential revenue growth outlook to more than 30% from more than 20%.

The company attributed the increase to higher-than-expected royalties from its first non-exclusive license for its Vertical Power Delivery technology. The upgraded outlook sparked a sharp move in after-hours trading Wednesday that continued into Thursday’s premarket session.

Monte Rosa Therapeutics surged 20% in premarket trading after announcing plans to present complete Phase 1 GFORCE-1 clinical results for MRT-8102, its NEK7-directed molecular glue degrader.

The company said the results would be presented during a live webcast at 8 a.m. ET Thursday. The upcoming data readout has become a key catalyst for investors following the announcement on Wednesday, with the stock extending its after-hours gains into the premarket session.

Constellation Energy rose 3.9% after announcing a 20-year power purchase agreement with Amazon covering 690 megawatts of nuclear power from the Calvert Cliffs Clean Energy Center in Maryland.

The agreement also includes about 190 megawatts of new emissions-free generating capacity expected to come online between 2030 and 2032, supported by more than $3 billion in infrastructure investment. The deal comes after Constellation shares suffered a sharp decline in the prior session on unrelated regulatory news.

Oracle (NYSE: ORCL) rose 1.6% after the Financial Times reported that Tencent had signed a $7 billion, five-year agreement with Oracle to access roughly 100,000 advanced AI chips across multiple Oracle data centers in Southeast Asia.

The arrangement reportedly includes an upfront payment of about 30% of the total contract value and is designed to give Tencent access to advanced chips that cannot be purchased directly in mainland China under current U.S. export restrictions.

Synopsys gained 2.5% after unveiling a multiyear agreement with Amazon Web Services valued at more than $1 billion.

Under the agreement, AWS will license Synopsys’ silicon intellectual property and engineering software for its custom-chip portfolio, including Nitro, Graviton and Trainium processors. Amazon will also become the lead customer for Synopsys’ expanded application-optimized IP business.

Nu Holdings (NYSE: NU) rose 3.9% to $13.15 as investors continued to recover from the steep losses earlier in the week triggered by reports that the Brazilian fintech company was considering acquiring U.K. digital bank Monzo at a valuation of £8 billion to £10 billion.

Nu said Wednesday that, while it has “a great deal of respect for Monzo,” it is not pursuing a transaction with the U.K. challenger bank. The clarification helped reverse some of the recent pressure on the shares.

Liquidia fell 5.2% to $28.70 after a Delaware federal court ruled that its YUTREPIA inhaled therapy infringed two claims of a United Therapeutics patent covering the treatment of pulmonary hypertension associated with interstitial lung disease.

The ruling adds another legal hurdle for Liquidia as it seeks to advance YUTREPIA, its lead therapy for pulmonary hypertension.

Zealand Pharma fell 11.7% after partner Boehringer Ingelheim released Phase 3 SYNCHRONIZE-2 results for survodutide, a dual glucagon/GLP-1 receptor agonist.

The trial met both co-primary endpoints, with patients achieving up to 13.1% average body-weight reduction compared with 3.1% for placebo over 76 weeks. Up to 79.3% of patients receiving survodutide lost at least 5% of their body weight.

BJ’s Restaurants rose 4.9% after Mizuho upgraded the casual-dining chain to Outperform from Neutral and raised its price target to $76 from $74.

The bank cited field checks pointing to stronger-than-expected third-quarter performance and raised its estimate for third-quarter same-store sales growth to 5.5% from 4.6%, above the Street consensus of 4.3%.

Original Article

Investing